AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15919435
Drug: Tacrolimus +
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus + low-dose Mycophenolate Mofetil (750 mg orally twice a day)
Trial: 15919435
Drug: Tacrolimus +
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus + low-dose Mycophenolate Mofetil (750 mg orally twice a day) + steroids
Trial: 12768289
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid (LA) 28.5 mg and gamma-linolenic acid (GLA) 15.1 mg, treated once daily orally from 3 days before PRK to 1 month after PRK
Trial: 12768289
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with LA and GLA)
Trial: 10814990
Drug: 0.8-fold dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8-fold dose of protamine (Group L)
Trial: 10814990
Drug: 2.0-fold dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0-fold dose of protamine (Group H)
Trial: 1519637
Drug: Diltiazem (120,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120, 240, 360, or 480 mg)
Trial: 1519637
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 mg/day for 2 weeks, 360 mg/day for 2 weeks, and then 540 mg/day for 2 weeks)
Trial: 6501124
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2 g latamoxef (moxalactam)
Trial: 6501124
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of latamoxef (moxalactam)
Trial: 25233856
Drug: TRK‐100STP 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRK‐100STP 60 μg b.i.d.
Trial: 25233856
Drug: TRK‐100STP 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRK‐100STP 120 μg b.i.d.
Trial: 22336172
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake of rye bread (99 g/d to 198 g/d)
Trial: 21163113
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg to 120 mg once daily
Trial: 21163113
Drug: Duloxetine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 120 mg once daily
Trial: 11077224
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) therapy
Trial: 10464707
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: IFN (alpha Interferon‐1,000,000 U/d), Cyclosporine A (CSA‐1 mg/kg/d intravenous) for 28 days, and GM‐CSF (250/m2/d) until engraftment
Trial: 10464707
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: CSA (1 mg/kg/d intravenous) and GM‐CSF
Trial: 10464707
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: CSA (1 mg/kg/d orally) and GM‐CSF
Trial: 7717013
Drug: Diltiazem (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (3 x 60 mg daily)
Trial: 7717013
Drug: Metoprolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (3 x 50 mg daily)
Trial: 29924771
Drug: Atorvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin therapy to achieve LDLC level less than 1.8 mmol/l
Trial: 29924771
Drug: Therapy to
RxNorm normalized name: COOL THERAPY Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy to achieve LDLC level below 2.6 mmol/l
Trial: 27145207
Drug: Soy food
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy food supplementation (50 mg isoflavones or 15 g soy protein in the form of tofu)
Trial: 20860662
Drug: VS411-2 formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS411-2 formulation (didanosine 400 mg and hydroxyurea 600 mg)
Trial: 18082885
Drug: Orbital radiation
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital radiation treatment
Trial: 9230329
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (500 mg twice daily for 10 days)
Trial: 3112672
Drug: No peritreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No peritreatment antibiotics (from previous study)
Trial: 9846530
Drug: Tacrolimus and
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus and prednisone (double-drug therapy)
Trial: 9846530
Drug: Tacrolimus, prednisone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus, prednisone, and mycophenolate mofetil (triple-drug therapy)
Trial: 22248502
Drug: BEET (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEET (140 ml/d of concentrated beetroot juice; 8 mmol/d nitrate)
Trial: 11781274
Drug: CNI-1493 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI-1493 (8 mg/m2 daily for 12 days)
Trial: 11781274
Drug: CNI-1493 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI-1493 (25 mg/m2 daily for 12 days)
Trial: 2682877
Drug: Home continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home continuous intravenous infusion chemotherapy (CVI)
Trial: 2682877
Drug: Inpatient continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient continuous intravenous infusion chemotherapy (CVI)
Trial: 5354851
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate (tablets)
Trial: 30376388
Drug: Massage (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage (20 min, twice a week for 12 weeks)
Trial: 25483979
Drug: 5-day discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day discontinuation of statin treatment
Trial: 25483979
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of statin treatment
Trial: 24085590
Drug: Tizanidine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine nasal spray (32.73 mg/mL) at doses of 2 mg and 4 mg
Trial: 24085590
Drug: Tizanidine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine nasal spray (16.36 mg/mL) at a dose of 1 mg
Trial: 24085590
Drug: Tizanidine oral
RxNorm normalized name: tizanidine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine oral tablets (4 mg)
Trial: 21943084
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy self management programme administered by a clinical psychologist over six consecutive weekly sessions (2 hours each)
Trial: 21943084
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (atypical analgesia and local anaesthetic injections)
Trial: 21943084
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy self management programme
Trial: 19068785
Drug: Bisphosphonates (alendronate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates (alendronate, risedronate) and raloxifene (selective estrogen receptor modulator)
Trial: 19068785
Drug: Pharmacotherapy based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy based on fracture risk factors
Trial: 19068785
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment for glucocorticoid- and diabetes mellitus-induced osteoporosis
Trial: 12606904
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of drug concentrations (propofol and remifentanil)
Trial: 8708127
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 50 mg/kg with hydroxyzine 25 mg (Group 1)
Trial: 8708127
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg/kg with acetaminophen elixir 10 mg/kg (Group 2)
Trial: 28121797
Drug: Immediate feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate feeding (IF) with CHO + PRO (1.5 g·kg BM dextrose and 0.5 g·kg BM whey) ingested immediately postexercise.
Trial: 28121797
Drug: Delayed feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed feeding (DF) with PLA ingested immediately postexercise and CHO + PRO solution 2 h postexercise.
Trial: 28121797
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) solution ingested immediately and 2 h postexercise.
Trial: 24979556
Drug: Probiotics (combination)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (combination)
Trial: 19233930
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L-Pop (3M Espe)
Trial: 17768467
Drug: Rocuronium Bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium Bromide 1 mg/kg
Trial: 3158243
Drug: Suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1 mg/kg
Trial: 31764782
Drug: Yiqi Huayu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Huayu Jiedu decoction (YHJD) combined with chemotherapy
Trial: 25888414
Drug: beta‐guanidinopropionic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐guanidinopropionic acid 100 mg
Trial: 12053590
Drug: Triamcinolone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (400 mg)
Trial: 11761821
Drug: Formoterol (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (24 mg)
Trial: 9418312
Drug: Interpleural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural block with 0.4 ml/kg bupivacaine, 0.5% before induction of general anesthesia, followed by continuous administration of bupivacaine 0.25%, 0.125 ml/kg/hr.
Trial: 2477909
Drug: Terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (120 mg)
Trial: 3306380
Drug: Triazolam 0.5
RxNorm normalized name: triazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.5 mg nightly for 7 to 10 nights (abrupt-withdrawal group)
Trial: 3306380
Drug: Tapered-dosage of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapered-dosage of triazolam: 0.5 mg for 7 nights, 0.25 mg for 2 nights, 0.125 mg for 2 nights (tapered-dosage group)
Trial: 3306380
Drug: Placebo (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (initial treatment for both groups)
Trial: 2508417
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive containing ethinylestradiol and gestodene
Trial: 31562800
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus veliparib followed by veliparib maintenance (veliparib throughout)
Trial: 31562800
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus veliparib followed by placebo maintenance (veliparib combination only)
Trial: 31562800
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus placebo followed by placebo maintenance (control)
Trial: 31562800
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus veliparib
Trial: 28526486
Drug: Fentanyl transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patches (50 μg hour−1)
Trial: 28526486
Drug: Fentanyl transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patches (75 μg hour−1)
Trial: 28526486
Drug: Fentanyl transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patches (100 μg hour−1)
Trial: 28526486
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patches (35 μg hour−1)
Trial: 28526486
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patches (70 μg hour−1)
Trial: 21272992
Drug: Intravesical administration
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical administration of hyaluronic acid (HA) and chondroitin sulphate (CS)
Trial: 11518093
Drug: 15-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-mg nicotine patch (16-hr)
Trial: 3115389
Drug: Stable strontium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable strontium absorption test with standard breakfast
Trial: 3115389
Drug: Stable strontium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable strontium absorption test
Trial: 3115389
Drug: Stable strontium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable strontium absorption test with food
Trial: 29953026
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser therapy (wavelength: 780 nm; fluence: 134 J/cm; power: 50 mW; irradiance: 1.675 W/cm; exposure time: 80 seconds per point) on 3 points of the masseter and 1 point on the anterior temporal muscles on each side
Trial: 26749451
Drug: Alfacalcidol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (0.25 μg daily for six months)
Trial: 23422606
Drug: Preparation of
RxNorm normalized name: kit for the preparation of Ga-68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of 2/3 (10.6 mm) of the total root length (G1 - control)
Trial: 23422606
Drug: Preparation of
RxNorm normalized name: kit for the preparation of Ga-68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of 1/2 (8 mm) of the total root length (G2)
Trial: 23422606
Drug: Preparation of
RxNorm normalized name: kit for the preparation of Ga-68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of 1/3 (5.3 mm) of the total root length (G3)
Trial: 20177860
Drug: Standardized 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized 200 ml of clear carbohydrate‐enriched drink orally 2 hours before surgery
Trial: 16614691
Drug: Lysine clonixinate
RxNorm normalized name: lysine clonixinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine clonixinate (LC) 250 mg
Trial: 16614691
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (NS) 550 mg
Trial: 12638395
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg single dose
Trial: 12638395
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg multiple doses (once daily for 10 days)
Trial: 12638395
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg with high-fat meal
Trial: 7112816
Drug: Catheters changed
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheters changed monthly as well as for infection and/or obstruction
Trial: 30515573
Drug: Telephone-based reminiscence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based reminiscence therapy (TBR)
Trial: 28742260
Drug: Optimal individualized
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal individualized treatment rule using preference elicitation questionnaire and item response theory
Trial: 26733563
Drug: Vitamin K3
RxNorm normalized name: Vitamin K3
DrugBank: Menadione (DB00170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin K3 acupuncture point injection
Trial: 26733563
Drug: Saline acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline acupuncture point injection
Trial: 26733563
Drug: Vitamin K3
RxNorm normalized name: Vitamin K3
DrugBank: Menadione (DB00170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin K3 deep muscle injection
Trial: 19158211
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid daily for 30 weeks
Trial: 19158211
Drug: 1.1 mg
RxNorm normalized name: menthol 1.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 mg folic acid daily for 30 weeks
Trial: 15101069
Drug: CD-ROM cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD-ROM cognitive-behavioral self-help treatment (8 sessions)
Trial: 8592249
Drug: Imidapril hydrochloride
RxNorm normalized name: imidapril hydrochloride
DrugBank: Imidapril (DB11783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril hydrochloride (5 mg once a day, increased to 10 mg if necessary)
Trial: 8592249
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate (5 mg once a day, increased to 10 mg if necessary)
Trial: 28320991
Drug: Risk score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk score model for contrast-induced nephropathy (CIN) based on age > 75 years, creatinine clearance (CrCl) < 60 mL/minute, and congestive heart failure (CHF)
Trial: 23421487
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) exposure at 100 μg/m³ PM₁₀ for 2 hours
Trial: 19332035
Drug: Various pharmacological
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various pharmacological agents including antidepressants, anti-adrenergic agents, anticonvulsants, benzodiazepines, atypical antipsychotics, and novel agents
Trial: 9456189
Drug: Epirubicin 130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 130 mg/m2 every 3 weeks until disease progression or cumulative dose of 1000 mg/m2 or heart failure occurred
Trial: 7856686
Drug: One subdermal
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One subdermal estradiol implant
Trial: 7856686
Drug: Three subdermal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three subdermal estradiol implants
Trial: 7856686
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (one and three implants)
Trial: 2159054
Drug: Intravenous vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vindesine (V) 3 mg/m2 every 2 weeks
Trial: 2159054
Drug: V 3
RxNorm normalized name: Ruta Grav 30X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V 3 mg/m2 weekly for 5 weeks plus mitomycin (VM) 20 mg/m2 day 1 and then 15 mg/m2 every 6 weeks
Trial: 2159054
Drug: V at
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: V at the more intensive dose rate plus cisplatin (VC) 120 mg/m2 with forced diuresis on days 1 and 29 and then every 6 weeks
Trial: 31095724
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (EVLA, dRFA, iRFA)
Trial: 25264565
Drug: Flupirtine IR
RxNorm normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine IR (100 mg)
Trial: 25264565
Drug: Flupirtine MR
RxNorm normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine MR (400 mg once daily for 8 days)
Trial: 21353585
Drug: Warm-blood cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm-blood cardioplegia supplemented with 16 mmol l⁻¹ Mg²⁺
Trial: 21353585
Drug: Warm-blood cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm-blood cardioplegia supplemented with 5 mmol l⁻¹ Mg²⁺
Trial: 19596563
Drug: Aerosol provocation
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosol provocation system (APS) using a single concentration of 16mg/mL methacholine (APS-SC)
Trial: 15271108
Drug: Practice style
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice style embodying traditional geriatric principles of care (prescribing no high-risk medications)
Trial: 11405513
Drug: Hydrocortisone 200
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 200 mg intravenously prior to salbutamol
Trial: 1295808
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) co-treatment